ArticleBritish journal of cancer2023
Use of methotrexate and risk of skin cancer: a nationwide case-control study.
Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Inflammatory Manifestations, Therapeutic Interventions, and Cancer Risk in Psoriasis: Current Epidemiological and Mechanistic Evidence.International journal of molecular sciences · 2026Review
- Risk of nonmelanoma skin cancer in patients with psoriatic arthritis and according to bDMARD treatment-a cohort study from the Nordic Arthritis Research Collaboration.EULAR rheumatology open · 2026Article
- Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!American journal of clinical dermatology · 2026Review
- Increased Risk of Hematologic Malignancy in Moderate to Severe Psoriasis in Relation to the Use of Systemic Immunosuppressants: A Nationwide Population-Based Matched Cohort Study.Journal of Korean medical science · 2025Article
- Treatment of Persons with Rheumatoid Arthritis with a History of Cancer.Current rheumatology reports · 2025Review
- Advances in the Medical Treatment of Rheumatoid Arthritis.Hand clinics · 2025Review
- Misfortunes never come alone: melanoma and ulcerative colitis after biologic therapy in a psoriatic patient - a case report and literature review.Frontiers in immunology · 2025Review
- Methotrexate - Safe Backbone for the Treatment of Rheumatoid Arthritis.Current rheumatology reviews · 2025Review
- The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review.Advances in therapy · 2024Review
- Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression.Cancers · 2024Review
- Hydrogel-based approaches to target hypersensitivity mechanisms underlying autoimmune disease.Advanced drug delivery reviews · 2024Review
- Skin Malignancies Due to Anti-Cancer Therapies.Cancers · 2024Review
- Risk Factors and Innovations in Risk Assessment for Melanoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma.Cancers · 2024Review
- Immune-Mediated Inflammatory Diseases and Cancer - a dangerous liaison.Frontiers in immunology · 2024Review
- Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- Review
- Safety of Dupilumab and Risk of Cutaneous T-Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data-Driven Guide to Counseling Patients and Families.Pediatric dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethotrexate (MTX) use has been suspected of increasing the risk of skin cancer. The aim of this investigation was to examine the association between the use of MTX and the risk of basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC) and cutaneous malignant melanoma (CMM).
methodsIn a nationwide Danish case-control study, we identified incident, histologically verified cases of BCC (n = 131,447), cSCC (n = 18,661) or CMM (26,068) from 2004 to 2018. We matched 10 controls to each case on sex and birth year using risk-set sampling and computed crude and adjusted odds ratios (ORs) using conditional logistic regression for the use of MTX (≥2.5 g) compared with never-use.
resultsUse of MTX was associated with increased risk of BCC, cSCC and CMM with adjusted ORs of (95% confidence interval) 1.29 (1.20-1.38), 1.61 (1.37-1.89) and 1.35 (1.13-1.61), respectively. For BCC and cSCC, ORs increased with higher cumulative doses. When restricting the study population to patients with psoriasis, the ORs were 1.43 (1.23-1.67), 1.18 (0.80-1.74) and 1.15 (0.77-1.72), respectively.
conclusionsWe observed an increased risk of BCC and cSCC associated with the use of MTX with evidence of a dose-response pattern; however, the association was not consistent when restricting the study population to patients with psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.